Trial Profile
A randomized, open-label, national multicenter, phase III trial studying maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and MLN9708 after autologous hematopoietic stem cell transplant in patients with newly-diagnosed, symptomatic multiple myeloma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms PETHEMA/GEM2014MAIN
- 12 Dec 2023 Results of an analysis assessing clinical impact of PRD and MRD dynamics in MM patients receiving intensive treatment from two clinical studies: GEM2012MENOS65 trial and GEM2014MAIN trial presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 28 Jul 2023 Results published in the Blood
- 13 Dec 2022 Results (n=156) assessing analyzed and compared the results and clinical impact of MRD evaluation in BM by NGF and in PB by quantitative immunoprecipitation mass-spectrometry (QIP-MS) during maintenance in patients enrolled in the GEM2014MAIN trial presented at the 64th American Society of Hematology Annual Meeting and Exposition